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Abstract
Background: Human Cripto-1, a member of the EGF-CFC family, is indispensable for early embryonic development.
Cripto-1 plays an important oncogenic role during tumorigenesis and is overexpressed in a wide range of epithelial
carcinomas, yet little is known about Cripto-1 in nasopharyngeal carcinoma (NPC). The aim of this study was to analyze
the roles of Cripto-1 in the progression and clinical characteristics in NPC clinical samples and cell lines.
Methods: The expression of Cripto-1 at mRNA level was detected by the reverse transcription-polymerase chain
reaction (RT-PCR) and real time RT-PCR, and western blot was used to examine the protein expression. Cripto-1
expression and its clinical characteristics were investigated by performing immunohistochemical analysis on a total of 37
NPC clinical tissue samples. Lentiviral vectors were constructed to get an efficient expression of anti-Cripto-1 siRNA in
CNE-2 and C666-1 cells, with invalid RNAi sequence as control. After the inhibition of the endogenous Cripto-1, the
growth, cell cycle and invasion of cells were detected by MTT, FACS and Boyden chamber assay respectively. Moreover,
in vivo, the proliferation of the tumor cells was evaluated in xenotransplant nude mice model with whole-body visualizing
instrument.
Results: The results of real-time RT-PCR and western blot showed that the expression level of Cripto-1 was markedly
higher in NPC cell lines than that in the immortalized nasopharyngeal epithelial cell at both mRNA and protein levels.
RT-PCR of 17 NPC tissues showed a high expression rate in 76.5% (13/17) cases. In an immunohistochemical study,
Cripto-1 was found to express in 54.1% (20/37) cases of NPC. In addition, Cripto-1 overexpression was significantly
associated with N classification (p = 0.034), distant metastasis (p = 0.036), and clinical stage (p = 0.007). Inhibition of
endogenous Cripto-1 by lentivirus-mediated RNAi silencing technique suppressed NPC cell growth and invasion in vitro.
In vivo, the average weight (p = 0.026) and volume (p = 0.044) of tumor in CNE-2/GFP+/Cripto-1- xenotransplant mice
group were significantly lower than those in the control group. The Ki67 index was obviously lower in Cripto-1 RNAi
treated tumors (p < 0.01).
Conclusion:  Data of this study suggest that Cripto-1 overexpression is connected with the tumorigenesis and
progression of NPC, lentivector-mediated RNAi might be feasible for the inhibition of the growth and invasion of NPC.
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Background
Nasopharyngeal carcinoma (NPC) is a distinctive type of
head and neck cancer with special racial and geographic
distributions. It is one of the most common cancers in
Southeast Asia and Southern China. The incidence rate of
NPC in Southern China (20-50/100,000 people per year)
is nearly 100-fold higher than that in the western
world[1]. Latent Epstein-Barr virus (EBV) infection is
uniquely present in almost all NPC from endemic regions,
whereas absent in NPC from nonendemic regions[2,3].
Additionally, NPC originates from a hidden anatomical
site, and is more closely associated with advanced clinical
stage with higher incidence of invasion and metastasis at
the time of diagnosis. Hence, the prognosis for NPC
patients is poor with a 5-year survival rate of less than
60%. It is of great clinical value to further understand the
molecular mechanism of this cancer and find valuable
early diagnostic markers as well as novel therapeutic strat-
egies.
Human Cripto-1, also known as teratocarcinoma-derived
growth factor-1 (TDGF-1), is a member of the Epidermal
growth factor-cripto FRL1 cryptic (EGF-CFC) family (Cripto
in humans, FRL1 in Xenopus, and Cryptic in mice), which
is indispensable for early embryonic development[4]. In
vivo, this 188-amino acid glycoprotein, Cripto-1 has two
activity patterns: as a cell surface co-receptor anchored by
glycosylphosphatidylinositol and as a soluble protein
after cleavage of the glycosylphosphatidylinositol link-
age[5]. Although identified as a marker for embryonic
stem cells and generally absent from adult tissues, Cripto-
1 is overexpressed in 75-80% of human breast, colon, and
lung cancers, as well as 50-60% of testicular, stomach,
pancreatic, and ovarian cancers[6]. Furthermore, Cripto-1
expression is significantly increased in premalignant
lesions, such as colon adenomas, intestinal metaplasia of
the gastric mucosa and ductal carcinoma in situ (DCIS) of
the breast[7]. Recently, it has been reported that plasma
Cripto-1 might represent a novel biomarker for the early
detection of breast and colon carcinomas[8]. In an addi-
tional study, combined analysis of Cripto-1 and E-cad-
herin has significant value in evaluating the metastatic
potential of gastric cancer and predicting patient progno-
sis[6]. In vitro and transgenic mice studies have shown
that cripto-1 play an important oncogenic role during
tumorigenesis by promoting cell proliferation, survival,
migration and invasion, as well inducing epithelial-to-
mesenchymal transition(EMT), transformation, branch-
ing morphogenesis and tumour angiogenesis[9,10].
Until now, there is never any evidence that has shown a
relationship between Cripto-1 expression and carcinogen-
esis of NPC. In this investigation, we examined the Cripto-
1 expression in human NPC in both clinical patient sam-
ples and tumour cell lines. We also used small hairpin
RNA (shRNA) technique based on lentivirus vector to spe-
cifically inhibit the expression of Cripto-1 in a NPC cell
line CNE-2. Our results provide strong evidences that
Cripto-1 is upregulated in human NPC and might play a
role in malignant progression of NPC.
Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-
1, SUNE-1, and HONE-1 were grown in RPMI-1640
medium (Hyclone, Logan, UT) supplemented with 10%
fetal calf serum (ExCell, Shanghai, China) and 1% L-
glutamine. NP69, a human immortalized nasopharyngeal
epithelial cell line[11], was grown in defined-KSFM
medium supplemented with EGF (Invitrogen, Carlsbad,
CA). Human embryonic kidney cell line 293FT was grown
in DMEM supplemented with 10% fetal calf serum
(Hyclone, Logan, UT). All cell lines were cultured at 37°C
in a humidified atmosphere of 5% CO2.
Patients and tissue specimens
A total of 37 primary NPC patients treated at the Nanfang
Hospital, Southern Medical University from 2006 to 2007
were enrolled to immunohitochemical study, including
26 males and 11 females with a median age of 49 years
(range, 24-82 years). Meantime, 17 samples out of these
37 patients and another 7 chronic nasopharyngitis tissue
samples were get freshly from the Nanfang Hospital,
Southern Medical University and frozen in liquid nitrogen
until process for RT-PCR examination. All patients were
not pretreated with radiotherapy or chemotherapy prior
to surgery. For the use of these clinical materials for
research purposes, prior consent of the patients and
approval from the Ethics Committee of Southern Medical
University were obtained. All specimens were confirmed
by pathological examination and staging was performed
according to the 1992 Fuzhou NPC staging system of
China[12,13].
Extraction of total RNA and RT-PCR
Total RNA was extracted from tissues and cell lines with
TRIzol (Invitrogen, Carlsbad, CA) according to the user
manual. cDNA was prepared from total RNA by using a
First Strand cDNA Synthesis kit (Roche, Indianapolis, IN).
Cripto-1 mRNA expressions were determined in 7 cell
lines by real-time RT-PCR and in 17 NPC tissue samples,
7 chronic nasopharyngitis tissue samples by RT-PCR anal-
ysis.
Expressions of Cripto-1 mRNA in NPC cell lines were
detected compared to that in NP69 cell line. For real-time
RT-PCR, each reaction was done on an MX3000P instru-
ment (Stratagene, Cedar Creek, TX) with the SYBR® Premix
Ex Taq™ kit (Takara bio, Otsu, Japan) in a 25 μl reaction
system with 1 μg cDNA following the manufacturer's pro-
tocol. ACTB (β-actin) was used as an internal control, and
measurements between samples were compared by theBMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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threshold cycle of amplification (CT). The fold change in
expression levels was determined by a comparative CT
method using the formula: 2-ΔΔCT(ΔΔCT = (CT(Cripto-1) -
CT(β-actin))cancer  - (CT(Cripto-1)  - CT(β-actin))NP69). Primer
sequences used for Cripto-1 are: forward 5'- GATACAG-
CACAGTAAGGAGC -3' and reverse 5'- TAGTTCT-
GGAGTCCTGGAAG -3'; for β-actin: forward 5'-
CACCCAGCACAATGAAGAT -3' and reverse 5'-
CAAATAAAGCCATGCCAAT -3'. The primers were
designed between different exons and encompassing large
introns to avoid any amplification of genomic DNA.
QPCR was performed for pre-denaturing at 95°C for 60
seconds, followed by 45 cycles (95°C for 15 seconds,
60°C for 60 seconds and 72°C for 30 seconds). Specificity
of amplification products was confirmed by melting curve
analysis. All reactions were repeated three times, and the
mean fold changes and standard deviation are reported.
For RT-PCR reactions, the thermal cycle was defined at
94°C for 5 min, followed by 40 cycles of denaturing at
94°C for 30 s, annealing at 60°C for 60 s and extension at
72°C for 30 s, and a final extension at 72°C for 10 min.
PCR products were electrophoresed in 1.5% agarose gels
and visualized by ethidium bromide staining to check for
nonspecific amplification.
Western-blot analysis
Cells were washed twice with cold PBS and lysed on ice in
RIPA buffer (1 × PBS, 1% NP40, 0.1% SDS, 5 mM EDTA,
0.5% sodium deoxycholate, and 1 mM sodium
orthovanadate) with protease inhibitors PMSF (Sangon,
Shanghai, China). After concentration measured by the
BCA method, equal amounts of protein were electro-
phoresed on 12% SDS/polyacrylamide gels and subse-
quently transferred to a polyvinylidene difluoride
membranes (PVDF) (Millipore, Billerica, MA) by elec-
troblotting. After blocking for 1 h in Tris buffered saline
(pH 7.6, containing 0.1% Tween and 5% non-fat milk) at
room temperature, membranes were incubated overnight
at 4°C with primary mouse monoclonal antibody against
Cripto-1 (R&D Systems, Minneapolis, MN, USA, at
1:1000 dilution), and β-actin (Abcam, Cambridge, UK, at
1:2000 dilution) with gentle shaking. After washing, the
membrane was then probed with the appropriate second-
ary antibody for 60 min at room temperature. Protein
binding on the membrane was detected by the enhanced
chemiluminescence (ECL) detection system (Pierce, Rock-
ford, IL) according to the manufacturer's instructions.
Then band intensity was measured by densitometry using
the Quantity One software (Bio-Rad, Hercules, CA). The
protein levels were normalized with respect to β-actin pro-
tein level.
Immunohistochemistry analysis
Sections (4 μm thick) of formalin fixed, paraffin wax
blocks were cut onto polylysine- coated microscope slides.
According to the specification of IHC S-P detection kit
(Maixin, Fujian, China): after deparaffinisation in xylene
and hydration through graded alcohol, sections were
washed and then exposed with ready-to-use proteinase K
solution (DakoCytomation, Carpinteria, CA) for 6 min-
utes at room temperature to enhance antigenicity. Endog-
enous peroxidase was blocked with 3% hydrogen
peroxide for 10 min and non-specific binding was
blocked with 5% normal goat serum in phosphate buff-
ered saline for 15 min. Then sections were incubated with
first antibody (mouse-anti-human Cripto-1 monoclonal
antibody, R&D Systems, Minneapolis, MN, USA) at a con-
centration of 1: 100 at 4°C overnight. Biotinylated anti-
mouse IgG antibody (Boshide, Wuhan, China) was added
for 15 min at 37°C, following the incubation with strepta-
vidin-biotin/horseradish peroxidase complex for 10 min
at 37°C. Finally, sections were colored with 3,3'-diami-
nobenzidine tetrahydrochloride (DAB) for 5 min, lightly
counterstained with hematoxylin and mounted. Sections
immunostained with PBS replacing primary antibody are
used as negative control. A positive control was included
with each batch of staining to ensure consistency between
consecutive runs.
Evaluation of staining
The brown-yellow staining of the cytoplasm and the cyto-
plasmic membrane was considered positive. For each
case, the entire stained tissue section was scanned, 5 visual
fields at 400× magnification were randomly chosen and
100 cells in each field were counted. The degree of immu-
nointensity was quantified by using the total immunos-
taining score calculated as the sum of the percent
positivity of stained tumour cells and the staining inten-
sity. The percent positivity was scored as '0' (<5%, nega-
tive), '1' (5-25%, sporadic), '2' (26-50%, focal), '3' (>50%,
diffuse). The staining intensity was score as '0' (no stain-
ing), '1' (weakly stained), '2' (moderately stained), and '3'
(strongly stained). Cases with weighted scores of less than
3 were defined as negative; otherwise they were defined as
positive[14]. No folding, and edging-effect fields were
chosen during calculation of 100 cells per five fields. The
score assessment was performed independently by two
pathologists blinded to the clinical parameters.
Construction of shRNA expressing vectors
The specific siRNA targeting sequence (5'-AATGACTCT-
GAATTAAAG-3')[15] is homologous to nt 190-208 of the
Cripto-1 mRNA(Gene Bank Accession No. NM_003312).
Short hairpin RNA (shRNA) was synthesized and cloned
into the pLVTHM vector, which contained H1 promoter
and a reporter gene green fluorescent protein (GFP). An
invalid RNAi sequence (5'-GCAGGAGCTATGCTAC-
CATCA-3') was used as negative control. The correct inser-
tion of the specific shRNA was further confirmed by
sequencing.BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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Treatment of NPC cells with shRNA-encoding expression 
construct
The Cripto-1-specific shRNA-encoding expression con-
struct (pLVTHM-shCripto-1), psPAX2 and pMD2.G were
cotransfected to 293FT cell line using the lipofectamine
2000 (Invitrogen, Carlsbad, CA) to produce lentivirus
stock, with negative construct as negative control. The
titration of lentiviral vectors were determined as described
by Tiscornia et al[16]. Briefly, the lentiviral preparation
was diluted tenfold serially in PBS (from undiluted to a
dilution of 10-5). 0.5 × 105 293FT cells were seeded in each
well of the 24-well plate, in a final volume of 500 μl per
well. Added 20 μl of each viral dilution to the cells, mixed
thoroughly but gently and incubated the cells at 37°C for
48 h. Cells were washed twice with PBS to eliminate left-
over virus in the medium. The percentage of labeled cells
was determined by FACS. Biological titer (BT = TU/ml,
transducing units) was calculated according to the follow-
ing formula: TU/μl = (P × N/100 × V) ×1/DF, where P = %
GFP+ cells, N = number of cells at time of transduction, V
= volume of dilution added to each well = 20 μl and DF =
dilution factor.
After the titer was determined, the lentivirus stock was
transduced to NPC cells according to the manufacture rec-
ommendations of BLOCK-iT™ Lentiviral RNAi Expression
System (Invitrogen, Carlsbad, CA). Cell lines with stable
Cripto-1 knock-down and the negative controls were
established by FACS selection for GFP expression and
named as CNE-2/GFP+/Cripto-1-, CNE-2/GFP+/mock,
C666-1/GFP+/Cripto-1- and C666-1/GFP+/mock, respec-
tively.
In vitro cell growth assay
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo-
lium bromide) (Sigma, St. Louis, MO, USA.) cell viability
assay, routine checks of the cell growth was performed to
assess the proliferation of the transduced cells. The cells
were incubated in 96-well microtiter plates at a density of
103 cells per well and cultured for 1-7 days. Each subse-
quent day, 20 μl of 5 mg/mL MTT were added to each
well. After being incubated for 4 h at 37°C, the superna-
tants were removed carefully. 150 μl of dimethyl sulfoxide
(Sigma, St. Louis, MO) were added to each well and thor-
oughly mixed for 10 minutes. The absorbance value (OD)
of each well was measured with a microplate reader (Bio-
Rad, Hercules, CA) set at 490 nm. All experiments were
performed in triplicate.
FACS analysis
Cell cycle distribution was analyzed by EPICS ACTRA
FACScan system (Beckman Coulter, US). 1 × 106 cells were
harvested, washed with ice-cold PBS, fixed by ice-cold
70% ethanol at 4°C overnight and labeled with DNAcon3
flow cytometry staining kit (Consults, Italy) according to
the manufacturer's instructions. All assays were performed
in triplicate, and the results were analyzed by Mod-fit soft-
ware (Becton-Dickson, Franklin Lakes, NJ, USA)
Tumour cell invasion assay
We used modifed Boyden chambers with filter inserts
(pore size, 8 μm) coated with Matrigel (Becton Dickinson
Labware) in 24-well dishes. Tumour cells in serum-free
medium (300 μl containing 1 × 105 cells) were added to
the top chamber. The bottom chamber was prepared with
10% FBS as a chemoattractant. After 48 h incubation, the
noninvasive cells were removed with a cotton swab. The
cells that had migrated through the membrane and had
stuck to the lower surface of the membrane were fixed
with methanol for 15 minutes and stained with haema-
toxylin. For quantification, the cells were counted under a
microscope in 5 predetermined fields at ×200.
In vivo experiments
The experimental protocol was approved by the Animal
Care and Use Committee of Nanfang Medical University.
A total of 5 mice, 4-5 weeks old and 18-20 g in weight,
were provided by the Central Animal Facility of Nanfang
Medical University and were bred in a specific pathogen-
free condition. All the 5 mice underwent subcutaneous
injection of 100 μl cell suspension of CNE-2 (1 × 106) in
the up axillary dorsal scapula region as control group, and
CNE-2/GFP+/Cripto-1-  (1 × 106) in the low inguinal
region. Tumor diameters were measured three times per
week with a caliper, and the volumes of tumors were cal-
culated by the following formula: a × b2/2, where a is the
largest diameter of the tumor and b is the shortest diame-
ter. GFP fluorescence images of the dopey mice were got
by an in vivo fluorescence instrument. All mice were sacri-
ficed 3 weeks after innoculation and tumors were har-
vested from mice and H&E (hematoxylin and eosin)
routine stains were executed. To examine the proliferative
activity of xenotransplant tumor after Cripto-1 gene
silencing, immunohistochemistry was performed to
detect the expression of Ki67 (rabbit-anti-human Ki67
polyclonal antibody, Boshide, Wuhan, China) in tumor
tissues and the percentages of tumor cells immunolabeled
for Ki67 were calculated. Approximately 1,000 cells were
counted in each section. Results are presented as means of
5 counts.
Statistical analysis
Quantitative values were expressed as means ± SD. All sta-
tistical analyses were performed in the SPSS 15.0 statisti-
cal software package. Fisher's exact test was used to
analyze the relationship between Cripto-1 expression and
clinicopathologic characteristics. Tumor cell invasion
assay, MTT assay and FACS analysis were tested by
ANOVA, with LSD test for multiple comparisons. Inde-
pendent-samples t- test was used to compare the values ofBMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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the test and control samples in vivo experiment. A p value
less than 0.05 was considered statistically significant.
Results
Expression analysis of Cripto-1 by real-time PCR, RT-PCR 
and western blot
To determine correlation of Cripto-1 with NPC, semi-
quantitative real-time PCR and western blot analysis were
performed to evaluate the expression levels of Cripto-1
transcripts and protein in an immortalized primary
nasopharyngeal epithelial cell line (NP69) and 6 NPC cell
lines (SUNE1, C666-1, CNE-2, CNE-1, HONE-1 and
HNE-1). As shown in Figure 1a and 1b, compared with
NP69 cell, the expression levels of Cripto-1 mRNA (p <
0.01) and protein (p < 0.05) are significantly up-regulated
in all 6 NPC cell lines (Detailed qRT-PCR data are shown
in additional file 1). Cripto-1 mRNA was highly expressed
in CNE-2 cell line with high metastatic ability, lowly
expressed in CNE-1 cell line with no metastatic ability,
and moderately in C666-1, SUNE-1, HONE-1 and HNE-
1, which indicated that CNE-2 cell line is a suitable cell
model for RNAi targeting Cripto-1 mRNA. In addition, we
included C666-1, which remains latently infected by EBV
in our study to better representative of NPC tumors. The
expression levels of Cripto-1 mRNA were also examined
in 17 NPC tissue samples, 7 chronic nasopharyngitis tis-
sue samples by semi-quantitative RT-PCR analysis.
Cripto-1 was higher expressed in 13 of 17 (76.5%) carci-
nomatous tissues compared with 2 of 7 (28.6%) control
inflammatory tissues (Table 1, p = 0.042) (Figure 1c).
Cripto-1 was overexpressed in NPC tissues
To investigate whether Cripto-1 abnormalities are linked
to human NPC, we analyzed Cripto-1 protein expression
in 37 paraffin-embedded, archival NPC tissues. Cripto-1
protein was detected in 20 (54.1%) cases. Cripto-1 stain-
ing was mostly observed in the cytoplasm and cytoplas-
mic membrane of carcinoma cells (Figure 2). No specific
Cripto-1 staining was observed in normal adjacent
nasopharyngeal epithelial cells and stroma cells in sur-
rounding tissues.
Relationship between clinicopathological features and 
Cripto-1 expression in NPC
The relationship between clinicopathological features and
Cripto-1 expression in NPC is summarized in Table 2.
Interestingly, we observed that Cripto-1 expression was
positively correlated with N classification (p= 0.034), dis-
tant metastasis (M classification, p = 0.036) and clinical
stage (p = 0.007) of NPC patients. With the evolvement of
NM stage and clinical stage, the positive rate of Cripto-1
expression in NPC tissues increased.
Lentivirus-mediated RNAi silencing inhibited the 
expression of Cripto-1 mRNA and protein in CNE-2 and 
C666-1 cell lines
To investigate whether Cripto-1 overexpression involves
in cell growth, cell cycle progression and invasive activity,
the CNE-2 and C666-1 cell lines were transduced with
recombinant lentivirus of small interference RNA target-
ing Cripto-1 and the negative control lentivirus (GFP+/
mock-lentivirus). After a selection of GFP expression by
FACS, we got CNE-2/GFP+/Cripto-1- and CNE-2/GFP+/
mock, C666-1/GFP+/Cripto-1-  and C666-1/GFP+/mock
sublines, with high percentages (more than 95%) of trans-
ductants expressed GFP, indicating a high and stable
transduction of lentiviral vector system. As shown in Fig-
ure 3, the results of quantitative RT-PCR and western blot
assays revealed that the expression of Cripto-1 in CNE-2/
GFP+/Cripto-1-  and C666-1/GFP+/Cripto-1-  were mark-
edly decreased compared to that in parent cells and nega-
tive controls (p < 0.05 respectively), which demonstrated
that RNAi technique was an effective way to modulate the
Cripto-1 expression in NPC cell lines.
Suppression of Cripto-1 expression decreased cell growth
As shown in Figure 4, after Cripto-1-shRNA-lentivirus
transduction, the growth of CNE-2/GFP+/Cripto-1- (F =
32.364, P < 0.01) and C666-1/GFP+/Cripto-1- cells(F =
44.772, P < 0.01) were evidently decreased. However, the
proliferation of control cells (CNE-2/GFP+/mock and
C666-1/GFP+/mock cells) showed no significant altera-
tion compared to parent cells during the time course.
These time-effect curves indicated that Cripto-1 knock-
down could inhibit the growth of NPC cells in vitro.
Cripto-1 knock-down wasn't involved in the regulation of 
cell cycle progression
To explore the possible underlying mechanisms of Cripto-
1 suppression in inhibiting CNE-2 cell growth, the effect
of Cripto-1 expression on cell cycle was analyzed by flow
cytometry. As shown in Table 3, no significant effect on
Table 1: mRNA Expression of Cripto-1 detected by RT-PCR in 17 NPC and 7 chronic nasopharyngitis tissue samples
mRNA expression
Sample positive negative Total p value
n% n %
NPC 13 76.5 4 23.5 17 0.042
chronic nasopharyngitis 2 28.6 5 71.4 7BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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the cell cycle of CNE-2 cells was observed after Cripto-1
knock-down.
Cripto-1 knock-down inhibited invasion of human NPC 
cells
On the other hand, we performed an invasion assay in a
modifed Boyden chamber to examine the effect of Cripto-
1 knock-down on the invasive potency of the CNE -2 cells
in vitro. Movement of cells through Matrigel-coated
Boyden chambers mimics the early steps of tumor inva-
sion. After cultivation for 48 h, the mean ± SD of cells
attached to the lower surface of the membrane of CNE-2-
treated different groups, as indicated previously, were as
follows: parent CNE-2, 106.4 ± 5.86; CNE-2/GFP+/mock,
102.6 ± 7.4; and CNE-2/GFP+/Cripto-1-, 49.2 ± 3.27.
Cripto-1 knock-down cells exhibited significantly reduced
invasive tendencies compared with the parent CNE-2 cells
and the CNE-2/GFP+/mock cells (F = 153.754, P < 0.01;
Figure 5). Therefore, disruption of endogenous Cripto-1
expression resulted in inhibition of cell invasion in NPC
cells.
Cripto-1 gene silencing suppressed proliferation of CNE-2 
cells in vivo
Of the 5 mice that were injected subcutaneously with 1 ×
106 CNE-2 and CNE-2/GFP+/Cripto-1- cells in up axillary
dorsal scapula region and low inguinal region respec-
tively, all of them developed evident tumors at the end of
this experiment. However, the mice treated with CNE-2/
GFP+/Cripto-1- cells showed that the growth of tumor was
significantly suppressed compared with those treated with
CNE-2 cells (Figure 6a, b and 6c). Three weeks after inoc-
ulation, the average tumor volume (0.410 ± 0.17 cm3) in
later group was significantly lower (p = 0.044) than that
(1.153 ± 0.67 cm3) in the former group. The average
tumor weight (0.51 ± 0.2 g) was lower (p = 0.026) than
Summary of Cripto-1 expressions in NPC cell lines and tissues Figure 1
Summary of Cripto-1 expressions in NPC cell lines and tissues. Expressions of Cripto-1 mRNA and protein in immor-
talized nasopharyngeal epithelial cell line (NP69), and NPC cell lines (SUNE-1, C666-1, HNE-1, HONE-1, CNE-1 and CNE-2) 
were examined by real-time RT-PCR (a) and Western blotting (b). Compared to NP69, Cripto-1 expressions were up-regu-
lated in all NPC cell lines (p < 0.05, respectively). (c) 1.5% agarose electrophoresis of Cripto-1 RT-PCR products in NPC tis-
sues. Representative results from 12 NPC cases are shown. β-actin was used as an internal quantitative control. M: Marker; 
1~6, 8, 9, 12: positive expression of Cripto-1 mRNA; 7, 10, 11: negative expression of Cripto-1 mRNA.BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
Page 7 of 14
(page number not for citation purposes)
Representative pictures of Cripto-1 expression evaluated by immunohistochemical staining in human NPC samples Figure 2
Representative pictures of Cripto-1 expression evaluated by immunohistochemical staining in human NPC 
samples. (a) and (b) Positive expression of Cripto-1 in WHO type I and III NPC samples (Original magnification ×400). (c) 
and (d) Positive expression of Cripto-1 in WHO type II NPC samples (Original magnification, ×100 and ×400, respectively). 
(e) and (f) Negative Cripto-1 staining of residual gland and normal nasopharyngeal epithelial tissue (arrow: residual gland and 
normal epithelial cells; Original magnification, ×100).BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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that in control group (1.49 ± 0.7 g) too. No obvious dif-
ference was found in body weight of mice in the treated
and control groups (data not shown). H&E stains showed
that all the tumor tissues were low-differentiation cell car-
cinoma (Figure 6d). Additionally, immunohistochemis-
try method exhibited that there was a significant
difference (p  < 0.01) in Ki67 index between the RNAi
group (49.2 ± 4.8%) and the control group (89.6 ± 3.4%)
(Figure 6e and 6f). These data indicate that Cripto-1 gene
silencing can suppress the proliferation of CNE-2 cells in
this experimental condition.
Discussion
Human Cripto-1 is increased in several types of cancer
and can function as an oncogene in vitro and  in
vivo[9,17,18]. However, there has been no report about
the relations between Cripto-1 and NPC. In this study, we
presented the first evidence that Cripto-1 was overex-
pressed at both transcriptional and translational levels in
NPC cell lines. Using immunochemistry and semi-quanti-
tative RT-PCR analysis, we found that Cripto-1 protein
was expressed in 54.1% (20 of 37 cases) and 76.5% (13 of
17 cases) human NPC tissues, respectively. However, only
28.6% (2 of 7 cases) nasopharygitis showed Cripto-1 pos-
itive. We also found that Cripto-1 overexpression was sig-
nificantly associated with N classification, distant
metastasis, and clinical stage. Our results highlight the
clinical significance of Cripto-1 in NPC. Expression of
Cripto-1 shows 50-80% variance, as detected by immuno-
histochemistry, in different types of tumour tissues. More
recently, Cripto-1 was detected in almost half of the breast
cancer tissue samples analyzed and found to correlate
with advanced stage disease[19]. Our results are consist-
ent with these reports and thus, NPC joins the list of the
tumors that express Cripto-1.
Until now, numerous in vitro and  in vivo studies have
shown that cripto-1 act as an important factor during tum-
origenesis by promoting cell proliferation, survival,
migration and invasion. Overexpression of Cripto-1
cDNA in normal mouse fibroblasts induce these cells to
grow in soft agar and increase growth rates in several
human breast cancer cell lines[20]. Human MCF-7 breast
cancer cells that overexpress Cripto-1 proliferate at higher
Table 2: Correlation between the clinicopathological features and expression of Cripto-1
Cripto-1
Clinicopathological
variables
Cases
(n = 37)
positive (%) negative (%) p value
n = 20 n = 17
Gender 0.627
Male 26 14 (53.8) 12 (46.2)
Female 11 6 (54.5) 5 (45.5)
Age(years)a 0.540
≤ 49 21 11(52.4) 10 (47. 6)
>49 16 9 (56.3) 7 (43.7)
Pathological classification(WHO) 0.062
Type I-II 17 12(70.6) 5 (29.4)
Type III 20 8 (40.0) 12 (60.0)
Depth of invasion
T classification
0.474
T1-2 27 14(51.9) 13 (48.1)
T3-4 10 6(60) 4(40)
Lymph node metastasis
N classification
0.034c
N0 9 2 (22.2) 7 (77.8)
N1-3 28 18(64.3) 10 (35.7)
Distant metastasis 0.036c
Yes 5 5(100.0) 0(0.0)
No 32 15 (48.4) 17(51.6)
Clinical Stagingb 0.007c
I-II 15 4 (26.7) 11 (73.3)
III-IV 22 16(72.7) 6(27.3)
agrouping of age was performed according to median.
bclinical staging was performed according to 1992 Fuzhou NPC staging system of China.
c statistical significance (p < 0.05)BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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rates in serum-free medium, form increased numbers of
colonies in soft agar, are more resistant to apoptosis when
grown under anchorage independent conditions, and
show increased propensity to invade and migrate in
vitro[21]. MMTV-Cripto-1 transgenic mice and WAP-
Cripto-1 transgenic mice that overexpress the human
Cripto-1 transgene showed increased incidence of mam-
mary gland tumors[9,18]. To explore the possible role of
Cripto-1 in promoting NPC cell proliferation and inva-
sion, we knocked down the expression of Cripto-1 in
CNE-2 and C666-1 by lentivirus-mediated RNAi silenc-
ing. Then through a continuous MTT assay, we found that
the cell growth was suppressed after the inhibition of
endogenous Cripto-1 protein, suggesting a role of Cripto-
1 in promoting tumor cell growth. However, flow cytom-
etry analysis showed no significant change on the cell
cycle of CNE-2 cells after Cripto-1 silence. This result sug-
gests that Cripto-1 might promote cell growth in other
pathway rather than impact on cell cycle. However, due to
high proliferative rate of CNE-2 cells and incomplete
RNAi suppressive effect (knock-down rather than knock-
out), the negative results of cell cycle analysis need to be
further verified.
To investigate the proliferation of the tumor cells in vivo
after Cripto -1 gene silencing, we employed the xenotrans-
plant nude mice model with whole-body visualizing
instrument. Data showed that both the average volume
and weight of tumor in CNE-2/GFP+/Cripto-1- xenotrans-
plant mice group were significantly lower than those in
Summary of Cripto-1 expression before and after lentivirus-mediated RNA interference Figure 3
Summary of Cripto-1 expression before and after lentivirus-mediated RNA interference. Real-time RT-PCR 
showed that the Cripto-1 mRNA in CNE-2 (a) and C666-1 cells (c) were effectively knockdown by RNAi. * p < 0.05. Protein 
expression were detected by western blot analysis, Cripto-1 were specifically inhibited in CNE-2/GFP+/Cripto-1- (b) and 
C666-1/GFP+/Cripto-1- cells (d). (p < 0.05, respectively).BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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the control group, indicating that the Cripto-1 gene silenc-
ing could partially inhibit the growth of CNE-2 cells in
vivo. Ki67, a nuclear protein regulating cell cycle, is a
biomarker of cell proliferation. Our results showed that
the number of cells immunolabeled for Ki67 in the CNE-
2/GFP+/Cripto-1- xenotransplant tumors was significantly
less than that in the control group, suggesting that a
decreased proliferation of CNE-2 cells could be achieved
by Cripto-1 knock-down.
Association of Cripto-1 with metastatic potential has been
found in a few human cancers. Ciardiello et al. have
reported that Cripto-1 mRNA expression is found in
68.2% (30/44) of primary colonic cancers and 61.8%
(21/34) of liver metastases, but in only 1.5% (1/65) of
normal tissues[22]. Furthermore, the Cripto-1 expression
level was increased in lymph node metastases compared
with their primary tumours[23]. In our study, Cripto-1
mRNA was highly expressed in CNE-2 and C666-1 cell
lines which are highly metastatic and proliferative. In the
contrary, in CNE-1 cell line with no metastatic ability,
Cripto-1 was expressed lowly. We also found Cripto-1
expression correlates with metastasis in NPC patients. In
addition, by in vitro invasion assay, substantial suppres-
sion of cell invasion was observed after endogenous
Cripto-1 interference. All of these data suggest an associa-
tion between Cripto-1 and tumour cell motility, invasion,
and metastasis. Thus, our studies have shown that Cripto-
1, as a potentially oncogenic protein, might play an
important role in the tumorigenesis and progression of
NPC.
However, the possible mechanism and the exact mode of
Cripto-1 action during tumor metastasis and progression
are still largely unknown. Although, we have not demon-
strated clearly the mechanisms underlined the inhibition
of Cripto-1 gene silencing, it has been evidenced that in
addition to functioning as a Nodal co-receptor, Cripto-1
has been shown to mediate signaling of other TGF-β lig-
ands, such as Activin and Xenopus Vg1 and its ortholog in
mouse GDF1[24]. In contrast, binding of Cripto-1 to
Activin and TGF-β1 can inhibit Activin and TGFβ-1 sign-
aling in mammalian cells[25]. Moreover, Cripto-1 can
also activate the ras/raf/MAPK and PI3-K/AKT/GSK-3β
intracellular signaling pathways independently of Nodal
and ALK4[26,27]. Some data suggest that Cripto-1 may be
involved in regulating integrin signaling either directly by
binding to integrins and subsequently activating integrin
signaling or indirectly by regulating the expression of
extracellular matrix proteins which are also capable of
binding integrins and activating integrin signaling[5]. Sev-
eral studies have also suggested that the Wnt/b-catenin/
Lef-1 signalling pathway may cross-talk with the Cripto-1
signaling pathway, regulating cell adhesion and migra-
tion[17,28,29]. Strizzi et al. have reported that Cripto-1
may promote the increased expression of markers and sig-
naling molecules associated with EMT[17]. Also, in the
Cripto-1 transgenic mammary gland tumors, the zinc-fin-
ger repressor transcription factor, Snail, known to down-
regulate or interfere with the normal expression of E-cad-
Growth curves of CNE-2 and C666-1 cell lines treated with  lentivirus mediated RNAi Figure 4
Growth curves of CNE-2 and C666-1 cell lines 
treated with lentivirus mediated RNAi. The cell 
growths were assessed by MTT method. Each value repre-
sents the mean ± SD of absorbance value (OD) for cells. 
CNE-2/GFP+/Cripto-1- cells (a) and C666-1/GFP+/Cripto-1- 
cells (b) exhibited a slower growth rate than that of the con-
trol cells. (p < 0.01, respectively).
Table 3: Percentage of G1, S, G2 stage cells of CNE-2, CNE-2/GFP+/mock and CNE-2/GFP+/Cripto-1- cells
Cell G1(%) S(%) G2(%)
CNE-2 53.95 ± 0.5 34.85 ± 2.39 11.25 ± 2.78
CNE-2/GFP+/MOCK 56.85 ± 3.7 34.175 ± 2.58 9.025 ± 1.79
CNE-2/GFP+/Cripto-1- 54.925 ± 4.94 34.25 ± 5.08 10.8 ± 2.11
p value 0.531 0.932 0.38BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
Page 11 of 14
(page number not for citation purposes)
herin, was detected at significantly higher levels as com-
pared to normal control mammary tissue, thus suggesting
a novel link between Cripto-1 expression and Snail activ-
ity[17].
Since high expression of Cripto-1 can be detected in
human cancers, as compared to normal tissues, this sign-
aling pathway might represent a target for cancer therapy.
This is supported by findings describing the use of anti-
sense oligonucleotides that reduce Cripto-1 expression
and cause significant reduction of cell proliferation in
vitro[30]. In addition, neutralizing antibodies against
Cripto-1 were able to significantly inhibit tumor cell
growth in two xenograft models with testicular and colon
cancer cells that express very high levels of Cripto-1[25].
Moreover, rat monoclonal antibodies directed against the
EGF-like domain of the Cripto-1 peptide also produced a
significant inhibition of in vitro and  in vivo growth of
colon cancer and leukemia cells[30,31]. Our data also
demonstrated that lentivector-mediated RNAi was feasi-
ble for the inhibition of the growth and invasion of NPC
cells in vitro and in vivo, indicating the siRNA sequences
targeting Cripto-1 could be a potential target for gene ther-
apy of NPC.
Conclusion
In summary, this study demonstrated that the level of
expression of Cripto-1 was significantly increased in NPC.
Moreover, Cripto-1 expression correlated evidently with
the malignant status of NPC. Finally, we showed that
Cripto-1 might play a role in the tumorigenesis and pro-
gression of NPC by promoting the growth and invasion of
NPC cells both in vitro and in vivo. These findings provide
new insight into understanding the molecular mechanism
involved in NPC carcinogenesis and progression, and may
lead to the development of new approaches for effective
diagnosis and therapy. However, more work is still
needed to clarify the mechanism of Cripto-1 in the devel-
Cripto-1 knock-down inhibited the invasion of CNE-2 cell lines Figure 5
Cripto-1 knock-down inhibited the invasion of CNE-2 cell lines. Effects of Cripto-1 knockdown on cell invasive 
potency were determined by an in vitro invasion assay. (A) 48 hr after seeded, the cells on the upper chambers were removed, 
and the invasive cells on the lower surface of the membrane were fixed and stained with hematoxylin, and visualized at ×200 
magnification. a: CNE-2, b: CNE-2/GFP+/mock, c: CNE-2/GFP+/Cripto-1-. (B) The cells on the lower surface of the membrane 
were counted in five randomly selected fields. Each value represents the average of triplicate determinations expressed as the 
mean ± SD. (* p < 0.01).BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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Cripto-1 gene silencing suppresses cell proliferation in vivo Figure 6
Cripto-1 gene silencing suppresses cell proliferation in vivo. (a) representative mouse bearing tumors (up was in CNE-
2 control group, down was in CNE-2/GFP+/Cripto-1- group). (b) external whole-body fluorescence images of the same mouse. 
(c) the external images of xenotransplant tumors (top was in CNE-2/GFP+/Cripto-1- group, bottom was in CNE-2 control 
group). (d) H&E stains of xenotransplant tumors, (×400). (e) expression of Ki67 in xenotransplant tumors of CNE-2 control 
group (×400). (f) expression of Ki67 in xenotransplant tumors of CNE-2/GFP+/Cripto-1- group (×400).BMC Cancer 2009, 9:315 http://www.biomedcentral.com/1471-2407/9/315
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opment and progression of NPC and its related signaling
pathway in NPC.
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